Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa.
Craig van RensburgRebecca BerhanuKamban HirasenDenise EvansSydney RosenLawrence LongPublished in: PloS one (2019)
Decentralized, outpatient RR/MDR-TB care under South Africa's 2011 strategy costs 74% less per patient than the previous strategy of inpatient care. The treatment cost of RR/MDR-TB is primarily driven by drug and staff costs, which are in turn dependant on treatment length.
Keyphrases
- south africa
- drug resistant
- multidrug resistant
- palliative care
- healthcare
- mycobacterium tuberculosis
- quality improvement
- hiv positive
- acinetobacter baumannii
- pain management
- affordable care act
- case report
- emergency department
- mental health
- hepatitis c virus
- pseudomonas aeruginosa
- hiv infected
- replacement therapy
- smoking cessation
- drug induced